MX2022006633A - Metodos de tratamiento del aumento de peso inducido por antipsicoticos con miricorilant. - Google Patents
Metodos de tratamiento del aumento de peso inducido por antipsicoticos con miricorilant.Info
- Publication number
- MX2022006633A MX2022006633A MX2022006633A MX2022006633A MX2022006633A MX 2022006633 A MX2022006633 A MX 2022006633A MX 2022006633 A MX2022006633 A MX 2022006633A MX 2022006633 A MX2022006633 A MX 2022006633A MX 2022006633 A MX2022006633 A MX 2022006633A
- Authority
- MX
- Mexico
- Prior art keywords
- antipsychotic
- gain
- weight gain
- grm
- methods
- Prior art date
Links
- 230000004584 weight gain Effects 0.000 title abstract 5
- 235000019786 weight gain Nutrition 0.000 title abstract 5
- 230000000561 anti-psychotic effect Effects 0.000 title abstract 3
- GVVUZBSCYAVFTI-IYARVYRRSA-N miricorilant Chemical compound FC(F)(F)C1=CC=CC(CC2=C(NC(=O)NC2=O)[C@H]2CC[C@@H](CC2)C2=CC=CC=C2)=C1 GVVUZBSCYAVFTI-IYARVYRRSA-N 0.000 title abstract 3
- 229940121462 miricorilant Drugs 0.000 title abstract 3
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 abstract 5
- 229940124604 anti-psychotic medication Drugs 0.000 abstract 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- YJDDXMSIMBMMGY-UHFFFAOYSA-N 2-cyclohexylpyrimidine Chemical compound C1CCCCC1C1=NC=CC=N1 YJDDXMSIMBMMGY-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 229960004170 clozapine Drugs 0.000 abstract 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960005017 olanzapine Drugs 0.000 abstract 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract 1
- 229960001534 risperidone Drugs 0.000 abstract 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen métodos y composiciones para tratar a un sujeto en riesgo de, o que sufre de aumento de peso inducido por antipsicóticos. Los métodos incluyen la administración de un modulador del receptor de glucocorticoides (GRM) de ciclohexil pirimidina tal como miricorilant (CORT118335) a un paciente que recibe, ha recibido o se espera que reciba un fármaco antipsicótico como olanzapina, risperidona, clozapina u otro medicamento antipsicótico inductor de peso. El GRM (por ejemplo, miricorilant) puede administrarse por vía oral. La administración de tal GRM junto con la medicación antipsicótica puede reducir la cantidad de peso, o reducir la tasa de aumento de peso, o prevenir el aumento de peso, que de otro modo se debería a la medicación antipsicótica sola. Los métodos pueden revertir el aumento de peso en un paciente al que se le administró previamente medicación antipsicótica. La administración de tal GRM con medicación antipsicótica puede reducir, o evitar el aumento, o prevenir el aumento, o revertir el aumento de la resistencia a la insulina o de los niveles sanguíneos de las enzimas hepáticas (AST, ALT), los triglicéridos o la insulina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962946957P | 2019-12-11 | 2019-12-11 | |
PCT/US2020/064520 WO2021119432A1 (en) | 2019-12-11 | 2020-12-11 | Methods of treating antipsychotic-induced weight gain with miricorilant |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022006633A true MX2022006633A (es) | 2022-06-24 |
Family
ID=76316599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022006633A MX2022006633A (es) | 2019-12-11 | 2020-12-11 | Metodos de tratamiento del aumento de peso inducido por antipsicoticos con miricorilant. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11903945B2 (es) |
EP (1) | EP4072556A4 (es) |
JP (1) | JP2023505948A (es) |
KR (1) | KR20220113767A (es) |
CN (1) | CN114929229A (es) |
AU (1) | AU2020400061A1 (es) |
CA (1) | CA3158745A1 (es) |
CL (1) | CL2022001250A1 (es) |
IL (1) | IL291775A (es) |
MX (1) | MX2022006633A (es) |
WO (1) | WO2021119432A1 (es) |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS322220B1 (es) | 1954-11-30 | 1957-04-11 | ||
DE3011809A1 (de) | 1980-03-27 | 1981-10-01 | Cassella Ag, 6000 Frankfurt | Pyrimidyl-chinazoline, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und ihre verwendung |
IL72729A (en) | 1983-09-26 | 1988-02-29 | Lilly Co Eli | Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them |
JPS6417555A (en) | 1987-07-13 | 1989-01-20 | Tokyo Electric Co Ltd | Facsimile |
US5008267A (en) | 1988-10-29 | 1991-04-16 | Mitsui Toatsu Chemicals, Incorporated | Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same |
GB8828669D0 (en) | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
JP3160941B2 (ja) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | カルバゾール誘導体および免疫抑制剤 |
JPH06128238A (ja) | 1992-10-20 | 1994-05-10 | Mitsui Toatsu Chem Inc | 新規ピリミジンジオン誘導体 |
FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
CA2168853A1 (en) | 1993-08-06 | 1995-02-16 | Giulio Dondio | Hydroisoquinoline derivatives |
EP0722732A1 (en) | 1995-01-24 | 1996-07-24 | Mitsui Toatsu Chemicals, Inc. | Long-acting drug formulation containing pyrimidinedione derivatives |
US5929058A (en) | 1996-12-24 | 1999-07-27 | Zymogenetics, Inc. | Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes |
CN1919199A (zh) | 1997-10-06 | 2007-02-28 | 利兰·斯坦福青年大学托管委员会 | 治疗糖皮质素功能失调相关性精神病的方法 |
AU756983B2 (en) | 1998-03-10 | 2003-01-30 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
NZ507449A (en) | 1998-05-15 | 2003-08-29 | Univ Leland Stanford Junior | Glucocorticoid receptor antagonists for the treatment of dementia |
GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
DE60113032T2 (de) | 2000-10-30 | 2006-07-06 | Pfizer Products Inc., Groton | Glukokortikoidrezeptor-Modulatoren |
GB0029100D0 (en) | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
WO2003015692A2 (en) | 2001-07-17 | 2003-02-27 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
JP2004537563A (ja) * | 2001-07-23 | 2004-12-16 | コーセプト セラピューティクス, インコーポレイテッド | 抗神経病薬誘導性体重増加を予防するための方法 |
JP4745609B2 (ja) | 2002-01-22 | 2011-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
US20030232813A1 (en) | 2002-04-10 | 2003-12-18 | Orchid Chemicals & Pharmaceuticals Limited | Novel amino substituted pyrimidinone derivatives |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
TWI327915B (en) * | 2003-06-12 | 2010-08-01 | Organon Nv | Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight |
BRPI0414066A (pt) | 2003-09-03 | 2006-10-24 | Wyeth Corp | 42-éster de rapamicina amorfo com ácido 3-hidróxi-2-( hidroximetil )-2-metilproipiÈnico e composições farmacêuticas que o contenha |
ATE407122T1 (de) | 2004-01-09 | 2008-09-15 | Corcept Therapeutics Inc | Azadecalinmodulatoren des glucocorticoidrezeptors |
WO2005087769A1 (en) | 2004-03-09 | 2005-09-22 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
NZ552984A (en) | 2004-07-02 | 2010-06-25 | Corcept Therapeutics Inc | Modified pyrimidine glucocorticoid receptor modulators |
CA2602781C (en) | 2005-04-05 | 2011-02-08 | F. Hoffmann-La Roche Ag | 1h-pyrazole 4-carboxylamides, their preparation and their use as 11beta-hydroxysteroid dehydrogenase |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
CN1965840A (zh) * | 2005-11-18 | 2007-05-23 | 科塞普特治疗公司 | 预防由抗精神病药物引起的体重增加的方法 |
US7640389B2 (en) | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
WO2009058944A2 (en) | 2007-11-01 | 2009-05-07 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof |
CA2622696A1 (en) * | 2007-11-05 | 2009-05-05 | Diane Mcintosh | Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs |
JP5637568B2 (ja) | 2009-05-12 | 2014-12-10 | コーセプト セラピューティクス, インコーポレイテッド | 固体形態および調製のためのプロセス |
US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
JP2013536250A (ja) | 2010-08-27 | 2013-09-19 | コーセプト セラピューティクス, インコーポレイテッド | ピリジル−アミン縮合アザデカリンモジュレーター |
CN103298343A (zh) | 2011-01-07 | 2013-09-11 | 科赛普特治疗公司 | 类固醇和糖皮质激素受体拮抗剂组合疗法 |
AU2012231265B2 (en) | 2011-03-18 | 2016-07-07 | Corcept Therapeutics, Inc. | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
LT3329919T (lt) | 2011-11-11 | 2020-02-10 | Gilead Apollo, Llc | Acc inhibitoriai ir jų panaudojimas |
US20130225633A1 (en) | 2012-02-27 | 2013-08-29 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
PL2861611T3 (pl) | 2012-05-25 | 2017-08-31 | Janssen Sciences Ireland Uc | Nukleozydy uracylowe spirooksetanu |
EP3851107B1 (en) | 2012-05-25 | 2022-10-19 | Corcept Therapeutics Incorporated | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
PT3848027T (pt) | 2013-11-25 | 2023-05-11 | Corcept Therapeutics Inc | Moduladores de recetores de glicocorticoides de azadecalina fundidas com octa-hidro |
US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
-
2020
- 2020-12-11 US US17/119,582 patent/US11903945B2/en active Active
- 2020-12-11 IL IL291775A patent/IL291775A/en unknown
- 2020-12-11 CA CA3158745A patent/CA3158745A1/en active Pending
- 2020-12-11 JP JP2022528536A patent/JP2023505948A/ja active Pending
- 2020-12-11 MX MX2022006633A patent/MX2022006633A/es unknown
- 2020-12-11 CN CN202080086165.9A patent/CN114929229A/zh active Pending
- 2020-12-11 WO PCT/US2020/064520 patent/WO2021119432A1/en unknown
- 2020-12-11 EP EP20900160.1A patent/EP4072556A4/en active Pending
- 2020-12-11 AU AU2020400061A patent/AU2020400061A1/en active Pending
- 2020-12-11 KR KR1020227023596A patent/KR20220113767A/ko unknown
-
2022
- 2022-05-12 CL CL2022001250A patent/CL2022001250A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021119432A1 (en) | 2021-06-17 |
EP4072556A4 (en) | 2024-01-03 |
CA3158745A1 (en) | 2021-06-17 |
JP2023505948A (ja) | 2023-02-14 |
KR20220113767A (ko) | 2022-08-16 |
US11903945B2 (en) | 2024-02-20 |
EP4072556A1 (en) | 2022-10-19 |
US20210177848A1 (en) | 2021-06-17 |
IL291775A (en) | 2022-06-01 |
AU2020400061A1 (en) | 2022-04-14 |
CN114929229A (zh) | 2022-08-19 |
CL2022001250A1 (es) | 2023-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pandina et al. | A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia | |
Deuker et al. | PI3′-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma | |
WO2005012485A3 (en) | Methods for treating diabetes and related disorders using pde10a inhibitors | |
Levy et al. | Safety, efficacy and management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension | |
PH12015501009B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
TN2016000500A1 (en) | Composition for Treating Diabetes Comprising Long-acting lnsulin Analogue Conjugale and Long-acting lnsulinotropic Peptide Conjugale | |
EP2216024A3 (en) | Use of Ranolazine for the treatment of cardiovascular diseases | |
MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
Alten et al. | Hypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approaches | |
WO2012154587A3 (en) | Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents | |
WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
EA201070557A1 (ru) | Способы и композиции для замедления набора веса, связанного с применением атипичных антипсихотических препаратов | |
MX2022006633A (es) | Metodos de tratamiento del aumento de peso inducido por antipsicoticos con miricorilant. | |
Zhou et al. | MnTBAP stimulates angiogenic functions in endothelial cells through mitofusin-1 | |
WO2006004696A3 (en) | Compositions and methods for the prevention and control of insulin-induced hypoglycemia | |
Ju et al. | Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety | |
Wang et al. | Pharmacokinetics, safety, and tolerability of rolapitant administered intravenously following single ascending and multiple ascending doses in healthy subjects | |
BR112022006748A2 (pt) | Métodos para tratar um indivíduo que sofre de ganho de peso e em risco de sofrer ganho de peso induzidos por antipsicótico | |
Sheikh et al. | THU0305 Pharmacokinetics of Switching from Intravenous To Subcutaneous Belimumab for Patients with Systemic Lupus Erythematosus (SLE) | |
Brümmendorf et al. | Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update | |
Cheng et al. | Combination therapy of traditional Chinese medicine and Western medicine to treat refractory polymyositis: a case report | |
Jani | Severe lactic acidosis: case report | |
Sat et al. | The usage of antihyperlipidemic agents in type 2 diabetic patients with hemodialysis in two public centers in Cambodia | |
LI et al. | Glutamine up-regulates GLP-1 expression in colon tissue of type 2 diabetic rats | |
ES2200192T3 (es) | Utilizacion de antagonista 5-ht 4 en la regulacion de la secrecion de los corticosteroides. |